Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats

Circulation Research

Volumn 84, Issue 6, 1999, Pages 722-728

  Zhang, Weiguo ^a   Kowal, Robert C ^a,b   Rusnak, Frank ^c   Sikkink, Robert A ^c   Olson, Eric N ^b   Victor, Ronald G ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Aortic banding; Calcineurin; Cyclosporin A; Left ventricular hypertrophy; Spontaneously hypertensive rat

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CALCINEURIN; CALMODULIN INHIBITOR; CYCLOSPORIN A; PROTEIN KINASE (CALCIUM,CALMODULIN); TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CLAMPING; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFECT; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

EID: 0033515618     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.6.722     Document Type: Article

References (36)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
2. Devereux RB, Roman MJ. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press Ltd; 1995:409-432.
3. Devereux RB. Left ventricular geometry, pathophysiology and prognosis. J Am Coll Cardiol. 1995;25:885-887.
4. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med. 1998;76:725-746.
5. Homcy CJ. Signaling hypertrophy: how many switches, how many wires. Circulation. 1998;97:1890-1892.
6. Kurtz TW, Gardner DG. Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension. 1998;32: 380-386.
7. 2+ currents in compensated hypertrophy and heart failure. Cardiovasc Res. 1998;37: 300-311.
8. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
9. 2+ response amplitude and duration. Nature. 1997;386:855-858.
10. 2+ oscillations. Science. 1998;279:227-230.
11. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281: 1690-1693.
12. Lipkin GW, Tucker B, Giles M, Raine AE. Ambulatory blood pressure and left ventricular mass in cyclosporin- and non-cyclosporin-treated renal transplant recipients. J Hypertens. 1993;11:439-442.
13. Gill EA, Borrego C, Bray BE, Renlund DG, Hammond EH, Gilbert EM. Left ventricular mass increases during cardiac allograft vascular rejection. J Am Coll Cardiol. 1995;25:922-926.
14. Ventura HO, Lavie CJ, Messerli FH, Valentino V, Smart FW, Stapleton DD, Ochsner JL. Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens. 1994;8:233-237.
15. Globits S, De Marco T, Schwitter J, Sakuma H, O'Sullivan M, Rifkin C, Keith F, Chatterjee K, Parmley WW, Higgins CB. Assessment of early left ventricular remodeling in orthotopic heart transplant recipients with cine magnetic resonance imaging: potential mechanisms. J Heart Lung Transplant. 1997;16:504-510.
16. Dart AM, Yeoh JK, Jennings GL, Cameron JD, Esmore DS. Circadian rhythms of heart rate and blood pressure after heart transplantation. J Heart Lung Transplant. 1992;11(4 pt 1):784-792.
17. Farge D, Julien J, Amrein C, Guillemain R, Vulser C, Mihaileanu S, Dreyfus G, Carpentier A. Effect of systemic hypertension on renal function and left ventricular hypertrophy in heart transplant recipients. J Am Coll Cardiol. 1990;15:1095-1101.
18. McKoy RC, Uretsky BF, Kormos R, Hardesty RL, Griffith BP, Salerni R. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol. 1988;62:1140-1142.
19. Grobecker HF, Riebel K, Wellenhofer T. Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. Clin Exp Pharmacol Physiol. 1995;22(suppl 1):S94-S95.
20. Mervaala EM, Pere AK, Lindgren L, Laakso J, Teravainen TL, Karjala K, Vapaatalo H, Ahonen J, Karppanen H. Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension. 1997;29:822-827.
21. Chin ER, Olson EN, Richardson JA, Yano Q, Humphries C, Shelton JM, Wu H, Zhu WG, Basselduby R, Williams RS. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998;12:2499-2509.
22. Malik AB, Shapiro JM, Yanics J, Rojales A, Geha AS. A simplified method for producing rapid ventricular hypertrophy in rats. Cardiovasc Res. 1974;8:801-805.
23. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Transplant Proc. 1990;22:1357-1361.
24. Rusnak F, Beressi AH, Haddy A, Tefferi A. Calcineurin protein phosphatase activity in peripheral blood lymphocytes. Bone Marrow Transplant. 1996;17:309-313.
25. 3 cells: direct evidence against dephosphorylation by calcineurin. J Membr Biol. 1997; 156:53-61.
26. Sambrook J, Fritsch EF, Maniatis T. In: Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989:1-24.
27. Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, Riegger GA, Schunkert H. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25: 250-259.
28. El Gamel A, Keevil B, Rahman A, Campbell C, Deiraniya A, Yonan N. Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection? J Heart Lung Transplant. 1997;16: 268-274.
29. Sander M, Lyson T, Thomas GD, Victor RG. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens. 1996;9: 121S-138S.
30. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;11(pt A):1325-1350.
31. Kaneko K, Susic D, Nunez E, Frohlich ED. ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am J Med Sci. 1997;314:21-27.
32. Gohlke P, Linz W, Scholkens B, Van Even P, Martorana P, Unger T. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study. Br J Clin Pract Symp. 1996;84(suppl):1-10.
33. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW Jr, Izumo S, Markham BE. Angiotensin II type 1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci USA. 1997;94:7543-7548.
34. Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN. Cis-acting sequences that mediate induction of β-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation. 1997;96:3943-3953.
35. Luo Z, Shyu K-G, Gualberto A, Walsh K. Calcineurin inhibitors and cardiac hypertrophy. Nat Med. 1998;4:1092-1093.
36. Müller JG, Nemoto S, Laser M, Carabello BA, Menick DR. Calcineurin inhibition and cardiac hypertrophy. Science. 1998;282:1007a. Available at: http://www.sciencemag.org/cgi/content/full/282/5391/1007a.